Privigen IVIg—safety and efficacy you can trust
Clinically proven to improve motor function in adults with CIDP
Privigen provides immunoglobulin G (IgG) antibodies that may help block your immune system from attacking the myelin. Even so, exactly how Privigen works is not completely understood.
Two clinical studies, named PRIMA and PATH, proved that Privigen is an effective treatment for CIDP
PATH evaluated Privigen in 207 people and is the largest CIDP study to date (PRIMA studied 28 people).
Safety and efficacy studied in the largest CIDP trial
PRIMA study
61%
of patients responded to Privigen
PATH study
73%
of patients responded to Privigen
Most study participants experienced improvements with Privigen IVIg in:
upper body
strength
grip
strength
lower body
strength
Privigen safety
97%
of side effects were
mild/moderate
In PRIMA and PATH, 97% of the side effects reported were mild or moderate in intensity.
Most common* Privigen side effects
- Headache
- Fatigue
- Nausea
- Fever
- High blood pressure
Two patients in the PRIMA study and 8 patients in PATH had serious side effects. These included hemolysis (2), exacerbation of CIDP (2), acute rash, increased blood pressure, hypersensitivity, pulmonary embolism, respiratory failure, and migraine.
These are not the only side effects possible; see the full prescribing information, including boxed warning, for a complete list of adverse reactions possible with treatment for each condition.
Call your doctor if you experience any side effects, or if you have any other questions or concerns.
*Occurring in more than 5% of people in the clinical trials.
Would you like to learn about Ig therapy that you can infuse yourself?
(Immune Globulin Subcutaneous
[Human] 20% Liquid)
Heritage of safety and
excellence
Receiving Privigen
therapy
The support
you need,
all in one place